1. a b Seedat S, Stein DJ. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trialInt Clin Psychopharmacol. (1999)
  2. a b c d Colazingari S, et al. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trialArch Gynecol Obstet. (2013)
  3. a b c d Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patientsEur Rev Med Pharmacol Sci. (2013)
  4. a b Agostini R, Rossi F, Pajalich R. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled studyEur Rev Med Pharmacol Sci. (2006)
  5. ^ Michell RH. The multiplying roles of inositol lipids and phosphates in cell control processesEssays Biochem. (1997)
  6. a b Parthasarathy R, Eisenberg F Jr. The inositol phospholipids: a stereochemical view of biological activityBiochem J. (1986)
  7. a b c d e Kaiser LG, et al. Scyllo-inositol in normal aging human brain: 1H magnetic resonance spectroscopy study at 4 TeslaNMR Biomed. (2005)
  8. a b Salloway S, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseNeurology. (2011)
  9. ^ Holub BJ. The nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and diseaseAdv Nutr Res. (1982)
  10. ^ Clements RS Jr, Reynertson R. Myoinositol metabolism in diabetes mellitus. Effect of insulin treatmentDiabetes. (1977)
  11. a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk Clements RS Jr, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol dietAm J Clin Nutr. (1980)
  12. a b c Dang NT, et al. D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 miceBiosci Biotechnol Biochem. (2010)
  13. ^ Balla T. Phosphoinositide-derived messengers in endocrine signalingJ Endocrinol. (2006)
  14. a b c Agranoff BW. Turtles All the Way: Reflections on myo-InositolJ Biol Chem. (2009)
  15. ^ Draskovic P, et al. Inositol hexakisphosphate kinase products contain diphosphate and triphosphate groupsChem Biol. (2008)
  16. ^ Mulugu S, et al. A conserved family of enzymes that phosphorylate inositol hexakisphosphateScience. (2007)
  17. ^ Shears SB. Assessing the omnipotence of inositol hexakisphosphateCell Signal. (2001)
  18. ^ Irvine RF. Inositide evolution – towards turtle dominationJ Physiol. (2005)
  19. ^ Irvine RF, Schell MJ. Back in the water: the return of the inositol phosphatesNat Rev Mol Cell Biol. (2001)
  20. a b Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseasesBiochimie. (2013)
  21. a b Shaldubina A, et al. Inositol deficiency diet and lithium effectsBipolar Disord. (2006)
  22. ^ Eisenberg F Jr, Parthasarathy R. Measurement of biosynthesis of myo-inositol from glucose 6-phosphateMethods Enzymol. (1987)
  23. ^ Deranieh RM, et al. Probing myo-inositol 1-phosphate synthase with multisubstrate adductsOrg Biomol Chem. (2012)
  24. a b c Asplin I, Galasko G, Larner J. chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjectsProc Natl Acad Sci U S A. (1993)
  25. ^ Kennington AS, et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitusN Engl J Med. (1990)
  26. a b Scioscia M, et al. Urinary excretion of inositol phosphoglycan P-type in gestational diabetes mellitusDiabet Med. (2007)
  27. a b Baillargeon JP, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndromeDiabetes Care. (2006)
  28. ^ Baillargeon JP, et al. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolismHum Reprod. (2008)
  29. ^ Stull AJ, et al. Relationships between urinary inositol excretions and whole-body glucose tolerance and skeletal muscle insulin receptor phosphorylationMetabolism. (2008)
  30. ^ Larner J, Craig JW. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistanceDiabetes Care. (1996)
  31. ^ Coady MJ, et al. Identification of a novel Na+/myo-inositol cotransporterJ Biol Chem. (2002)
  32. ^ Ostlund RE Jr, et al. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-{3-3H}inositolJ Biol Chem. (1996)
  33. ^ Gullapalli RP. Soft gelatin capsules (softgels)J Pharm Sci. (2010)
  34. a b Carlomagno G, et al. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical useExpert Opin Drug Deliv. (2012)
  35. a b c Gianfranco C, et al. Myo-inositol in the treatment of premenstrual dysphoric disorderHum Psychopharmacol. (2011)
  36. ^ Larner J. D-chiro-inositol–its functional role in insulin action and its deficit in insulin resistanceInt J Exp Diabetes Res. (2002)
  37. ^ Sun TH, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controlsBiochem Biophys Res Commun. (2002)
  38. a b c Yamashita Y, et al. Detection of orally administered inositol stereoisomers in mouse blood plasma and their effects on translocation of glucose transporter 4 in skeletal muscle cellsJ Agric Food Chem. (2013)
  39. a b c Kofman O, et al. Chronic dietary inositol enhances locomotor activity and brain inositol levels in ratsPsychopharmacology (Berl). (1998)
  40. ^ Agam G, et al. High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithiumPharmacol Biochem Behav. (1994)
  41. ^ Patishi Y, et al. Differential uptake of myo-inositol in vivo into rat brain areasEur Neuropsychopharmacol. (1996)
  42. ^ Spector R. Myo-inositol transport through the blood-brain barrierNeurochem Res. (1988)
  43. ^ Kofman O, et al. Restoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizuresPsychopharmacology (Berl). (1993)
  44. ^ Levine J, et al. Inositol treatment raises CSF inositol levelsBrain Res. (1993)
  45. ^ Shimon H, et al. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorderAm J Psychiatry. (1997)
  46. ^ Manji HK, et al. Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositolNeuropsychopharmacology. (1996)
  47. a b Levine J, et al. Double-blind, controlled trial of inositol treatment of depressionAm J Psychiatry. (1995)
  48. ^ Levine J, et al. Follow-up and relapse analysis of an inositol study of depressionIsr J Psychiatry Relat Sci. (1995)
  49. a b Gelber D, Levine J, Belmaker RH. Effect of inositol on bulimia nervosa and binge eatingInt J Eat Disord. (2001)
  50. ^ Nemets B, et al. Inositol addition does not improve depression in SSRI treatment failuresJ Neural Transm. (1999)
  51. ^ Levine J, et al. Combination of inositol and serotonin reuptake inhibitors in the treatment of depressionBiol Psychiatry. (1999)
  52. a b c Inositol 6 g daily may be effective in depression but not in schizophrenia.
  53. ^ Zukov I, et al. Premenstrual dysphoric disorder–review of actual findings about mental disorders related to menstrual cycle and possibilities of their therapyPrague Med Rep. (2010)
  54. a b Nemets B, et al. Myo-inositol has no beneficial effect on premenstrual dysphoric disorderWorld J Biol Psychiatry. (2002)
  55. ^ Chengappa KN, et al. Inositol as an add-on treatment for bipolar depressionBipolar Disord. (2000)
  56. ^ Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepinesJ Psychiatr Res. (2010)
  57. ^ Qureshi NA, Al-Bedah AM. Mood disorders and complementary and alternative medicine: a literature reviewNeuropsychiatr Dis Treat. (2013)
  58. ^ Nierenberg AA, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidoneAm J Psychiatry. (2006)
  59. ^ Cohen H, et al. Inositol has behavioral effects with adaptation after chronic administrationJ Neural Transm. (1997)
  60. ^ Einat H, et al. Chronic epi-inositol has an anxiolytic-like effect in the plus-maze model in ratsInt J Neuropsychopharmacol. (1998)
  61. ^ Kofman O, et al. The anxiolytic effect of chronic inositol depends on the baseline level of anxietyJ Neural Transm. (2000)
  62. a b Palatnik A, et al. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorderJ Clin Psychopharmacol. (2001)
  63. ^ Benjamin J, et al. Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorderJ Psychiatr Res. (1997)
  64. ^ Benjamin J, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorderAm J Psychiatry. (1995)
  65. ^ Kaplan Z, et al. Inositol treatment of post-traumatic stress disorderAnxiety. (1996)
  66. a b Levine J, et al. CSF inositol in schizophrenia and high-dose inositol treatment of schizophreniaEur Neuropsychopharmacol. (1994)
  67. ^ Levine J, et al. Lack of effect of inositol treatment in chronic schizophreniaBiol Psychiatry. (1993)
  68. ^ Fux M, et al. Inositol treatment of obsessive-compulsive disorderAm J Psychiatry. (1996)
  69. ^ Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression.
  70. ^ Kofman O, et al. The effect of peripheral inositol injection on rat motor activity models of depressionIsr J Med Sci. (1993)
  71. ^ Levine J, et al. Lack of effect of 6 g inositol treatment of post-ECT cognitive function in humansJ Psychiatr Res. (1995)
  72. ^ Michaelis T, et al. Identification of Scyllo-inositol in proton NMR spectra of human brain in vivoNMR Biomed. (1993)
  73. ^ Frahm J, et al. Localized proton NMR spectroscopy of brain tumors using short-echo time STEAM sequencesJ Comput Assist Tomogr. (1991)
  74. ^ Seaquist ER, Gruetter R. Identification of a high concentration of scyllo-inositol in the brain of a healthy human subject using 1H- and 13C-NMRMagn Reson Med. (1998)
  75. a b Fenili D, et al. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathologyJ Mol Med (Berl). (2007)
  76. a b McLaurin J, et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicityJ Biol Chem. (2000)
  77. a b Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathwayJ Neurosci. (2007)
  78. ^ McLaurin J, et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse modelNat Med. (2006)
  79. ^ Townsend M, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomersAnn Neurol. (2006)
  80. ^ Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men.
  81. ^ Barak Y, et al. Inositol treatment of Alzheimer’s disease: a double blind, cross-over placebo controlled trialProg Neuropsychopharmacol Biol Psychiatry. (1996)
  82. ^ Levine J, et al. Inositol treatment of autismJ Neural Transm. (1997)
  83. ^ Brosche T. Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic valuesArch Gerontol Geriatr. (2001)
  84. a b Maeba R, et al. Plasmalogens in human serum positively correlate with high- density lipoprotein and decrease with agingJ Atheroscler Thromb. (2007)
  85. ^ Bräutigam C, et al. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresisAtherosclerosis. (1996)
  86. ^ Maeba R, Ueta N. Determination of choline and ethanolamine plasmalogens in human plasma by HPLC using radioactive triiodide (1-) ion (125I3-)Anal Biochem. (2004)
  87. a b Maeba R, et al. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndromeJ Nutr Sci Vitaminol (Tokyo). (2008)
  88. ^ Saltiel AR. Second messengers of insulin actionDiabetes Care. (1990)
  89. ^ Caro HN, et al. Isolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liverBiochem Mol Med. (1997)
  90. a b McLean P, et al. Reciprocal control of pyruvate dehydrogenase kinase and phosphatase by inositol phosphoglycans. Dynamic state set by “push-pull” systemJ Biol Chem. (2008)
  91. ^ Roche TE, et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoformsProg Nucleic Acid Res Mol Biol. (2001)
  92. ^ Denton RM, et al. The hormonal regulation of pyruvate dehydrogenase complexAdv Enzyme Regul. (1996)
  93. ^ Harris RA, et al. Regulation of the activity of the pyruvate dehydrogenase complexAdv Enzyme Regul. (2002)
  94. ^ Cohen P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal LectureEur J Biochem. (2001)
  95. ^ Cohen P. The origins of protein phosphorylationNat Cell Biol. (2002)
  96. a b Kunjara S, et al. Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changesMol Genet Metab. (1999)
  97. ^ Shashkin PN, et al. Insulin mediators in man: effects of glucose ingestion and insulin resistanceDiabetologia. (1997)
  98. ^ Larner J. D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at workIUBMB Life. (2001)
  99. a b Dugani CB, Klip A. Glucose transporter 4: cycling, compartments and controversiesEMBO Rep. (2005)
  100. ^ Farese RV, Sajan MP, Standaert ML. Atypical protein kinase C in insulin action and insulin resistanceBiochem Soc Trans. (2005)
  101. ^ Ng Y, et al. Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytesCell Metab. (2008)
  102. ^ Randhawa VK, et al. GLUT4 vesicle recruitment and fusion are differentially regulated by Rac, AS160, and Rab8A in muscle cellsJ Biol Chem. (2008)
  103. a b Ijuin T, Takenawa T. Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP)J Biol Chem. (2012)
  104. ^ Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell functionJ Biol Chem. (1999)
  105. ^ Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4Nat Rev Mol Cell Biol. (2002)
  106. a b c Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling conceptsJ Neurochem. (2007)
  107. ^ Tanti JF, et al. Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytesJ Biol Chem. (1996)
  108. ^ Kotani K, et al. Requirement for phosphoinositide 3-kinase in insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytesBiochem Biophys Res Commun. (1995)
  109. ^ Kanai F, et al. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinaseBiochem Biophys Res Commun. (1993)
  110. ^ Furuichi T, et al. Intracellular channelsCurr Opin Neurobiol. (1994)
  111. ^ Iwai M, et al. Molecular cloning of mouse type 2 and type 3 inositol 1,4,5-trisphosphate receptors and identification of a novel type 2 receptor splice variantJ Biol Chem. (2005)
  112. ^ Co-expression in vertebrate tissues and cell lines of multiple inositol 1,4,5-trisphosphate (InsP3) receptors with distinct affinities for InsP3.
  113. ^ Nakashima N, et al. The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytesJ Biol Chem. (2000)
  114. ^ Stiles B, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity {corrected}Proc Natl Acad Sci U S A. (2004)
  115. ^ Kurlawalla-Martinez C, et al. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissueMol Cell Biol. (2005)
  116. ^ Wada T, et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activityMol Cell Biol. (2001)
  117. ^ Sasaoka T, et al. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubesDiabetologia. (2001)
  118. ^ Sleeman MW, et al. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesityNat Med. (2005)
  119. ^ Ijuin T, Takenawa T. SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formationMol Cell Biol. (2003)
  120. ^ Ijuin T, et al. Increased insulin action in SKIP heterozygous knockout miceMol Cell Biol. (2008)
  121. ^ Kong AM, et al. Phosphatidylinositol 3-phosphate {PtdIns3P} is generated at the plasma membrane by an inositol polyphosphate 5-phosphatase: endogenous PtdIns3P can promote GLUT4 translocation to the plasma membraneMol Cell Biol. (2006)
  122. ^ Taguchi A, et al. Identification of Glypican3 as a novel GLUT4-binding proteinBiochem Biophys Res Commun. (2008)
  123. ^ Kawa JM, Taylor CG, Przybylski R. Buckwheat concentrate reduces serum glucose in streptozotocin-diabetic ratsJ Agric Food Chem. (2003)
  124. ^ Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitolBr J Pharmacol. (2000)
  125. a b Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives.
  126. ^ Giordano D, et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled studyMenopause. (2011)
  127. a b Santamaria A, et al. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndromeClimacteric. (2012)
  128. a b c Corrado F, et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetesDiabet Med. (2011)
  129. a b D’Anna R, et al. Myo-inositol may prevent gestational diabetes in PCOS womenGynecol Endocrinol. (2012)
  130. ^ Chau JF, et al. Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nervesFASEB J. (2005)
  131. ^ Grant PS, Lipscomb D. How often do we ask about erectile dysfunction in the diabetes review clinic? Development of a neuropathy screening toolActa Diabetol. (2009)
  132. ^ Hecht MJ, et al. Neuropathy is a major contributing factor to diabetic erectile dysfunctionNeurol Res. (2001)
  133. a b c d Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trialEur Rev Med Pharmacol Sci. (2003)
  134. a b c d Genazzani AD, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patientsGynecol Endocrinol. (2012)
  135. a b Donà G, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndromeEur J Endocrinol. (2012)
  136. a b Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation aloneEur Rev Med Pharmacol Sci. (2012)
  137. ^ Gerli S, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOSEur Rev Med Pharmacol Sci. (2007)
  138. a b c Carmina E. PCOS: metabolic impact and long-term managementMinerva Ginecol. (2012)
  139. ^ Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysisHippokratia. (2009)
  140. ^ Broekmans FJ, et al. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factorsBJOG. (2006)
  141. ^ Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: a practical guideDrugs. (2006)
  142. ^ Cascella T, et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndromeHum Reprod. (2008)
  143. ^ Ciampelli M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndromeMetabolism. (1999)
  144. ^ Metformin in polycystic ovary syndrome: systematic review and meta-analysis.
  145. ^ Unfer V, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trialsGynecol Endocrinol. (2012)
  146. a b c d Artini PG, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized studyGynecol Endocrinol. (2013)
  147. a b c Costantino D, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trialEur Rev Med Pharmacol Sci. (2009)
  148. ^ Genazzani AD, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndromeGynecol Endocrinol. (2008)
  149. a b Papaleo E, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation inductionGynecol Endocrinol. (2007)
  150. ^ Ciotta L, et al. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trialEur Rev Med Pharmacol Sci. (2011)
  151. ^ Lisi F, et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot studyReprod Biol Endocrinol. (2012)
  152. ^ Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS womenGynecol Endocrinol. (2010)
  153. ^ Hazell AS, Butterworth RF. Hepatic encephalopathy: An update of pathophysiologic mechanismsProc Soc Exp Biol Med. (1999)
  154. ^ Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathyJ Cereb Blood Flow Metab. (1991)
  155. ^ Shawcross DL, et al. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemiaAm J Physiol Gastrointest Liver Physiol. (2004)
  156. ^ Lien YH, et al. Scyllo-inositol depletion in hepatic encephalopathyLife Sci. (1994)
  157. ^ Binesh N, et al. Hepatic encephalopathy: a neurochemical, neuroanatomical, and neuropsychological studyJ Appl Clin Med Phys. (2006)
  158. a b Wattenberg LW, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositolCarcinogenesis. (2000)
  159. ^ Hecht SS, et al. Dose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzoCancer Lett. (2001)
  160. ^ Estensen RD, Wattenberg LW. Studies of chemopreventive effects of myo-inositol on benzo{a}pyrene-induced neoplasia of the lung and forestomach of female A/J miceCarcinogenesis. (1993)
  161. a b c Lam S, et al. A phase I study of myo-inositol for lung cancer chemopreventionCancer Epidemiol Biomarkers Prev. (2006)
  162. ^ Zacchè MM, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndromeGynecol Endocrinol. (2009)
  163. a b Skoven I, Thormann J. Lithium compound treatment and psoriasisArch Dermatol. (1979)
  164. a b Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and managementAm J Clin Dermatol. (2000)
  165. a b Williams RS, et al. A common mechanism of action for three mood-stabilizing drugsNature. (2002)
  166. a b The effect of inositol on lithium-induced polyuria—polydipsia in rats and humans.
  167. a b c Allan SJ, et al. The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trialBr J Dermatol. (2004)
  168. ^ Cupisti S, et al. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOSExp Clin Endocrinol Diabetes. (2007)
  169. ^ Mueller A, et al. Endocrinological markers for assessment of hyperandrogenemia in hirsute womenHorm Res. (2007)
  170. ^ Minozzi M, D’Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical studyReprod Biomed Online. (2008)
  171. ^ Smith DF. Lithium orotate, carbonate and chloride: pharmacokinetics, polyuria in ratsBr J Pharmacol. (1976)
  172. ^ Minozzi M, et al. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndromeGynecol Endocrinol. (2011)
  173. ^ Galletta M, et al. Bye-bye chiro-inositol – myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation inductionEur Rev Med Pharmacol Sci. (2011)
  174. ^ Isabella R, Raffone E. Does ovary need D-chiro-inositolJ Ovarian Res. (2012)
  175. ^ Tantivejkul K, Vucenik I, Shamsuddin AM. Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: II. Effects on integrins and focal adhesionsAnticancer Res. (2003)
  176. ^ Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agentLife Sci. (1997)
  177. ^ Singh RP, et al. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factorClin Cancer Res. (2004)
  178. ^ Bohn T, et al. Phytic acid added to white-wheat bread inhibits fractional apparent magnesium absorption in humansAm J Clin Nutr. (2004)
  179. ^ Larsson M, et al. Improved zinc and iron absorption from breakfast meals containing malted oats with reduced phytate contentBr J Nutr. (1996)
  180. ^ Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinicJ Nutr. (2003)
  181. ^ Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositolNutr Cancer. (2006)
  182. ^ Tantivejkul K, et al. Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancerBreast Cancer Res Treat. (2003)
  183. a b Bacić I, et al. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical studyJ Exp Clin Cancer Res. (2010)
  184. ^ Unfer V, et al. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort studyGynecol Endocrinol. (2011)
  185. a b Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trialEur Rev Med Pharmacol Sci. (2010)
  186. ^ Carlomagno G, Unfer V. Inositol safety: clinical evidencesEur Rev Med Pharmacol Sci. (2011)
  187. Unfer V, et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trialEur Rev Med Pharmacol Sci. (2011)
  188. Iuorno MJ, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndromeEndocr Pract. (2002)
  189. Papaleo E, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trialFertil Steril. (2009)